Orsini, a leader in rare disease pharmacy solutions, announced today that it is the single-source specialty pharmacy partner for Glaukos' Epioxa, a novel, groundbreaking advancement in corneal ...

Epioxa, the first FDA-approved epithelium-on cross-linking procedure, is now commercially available, according to a press ...

Glaukos Corporation GKOS recently announced the commercial availability of Epioxa, marking a significant milestone in its corneal health portfolio. The therapy stands out as the first FDA-approved, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Most eyes with keratoconus or corneal ectasia after ...

Keratoconus is a rare, progressive ophthalmic disorder characterized by changes to the cornea that result in significant ...

Credit: Glaukos. Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.

Commercial rollout includes direct purchasing and specialty distribution, alongside scaled investments in awareness, ...

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug ...

(MASS APPEAL) – If you’ve been diagnosed with Keratoconus then Corneal Cross Linking might get you back to better eyesight. Mass Appeal’s Patrick Berry joined Dr. John P. Frangie, MD to learn more.